






















httpLow levels of a natural IgM antibody are associated
with vein graft stenosis and failure
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Background: All humans have natural, protective antibodies directed against phosphorylcholine (PC) epitopes, a common
inﬂammatory danger signal appearing at sites of cell injury, oxidative stress, and on bacterial capsules. In large human
cohorts, low levels of anti-PC IgM were associated with a signiﬁcantly increased risk of stroke or myocardial infarction.
However, it is not known if these antibodies protect against the premature closure of arterial reconstructions.
Methods: A prospective, observational study of patients undergoing elective, infrainguinal, autogenous vein bypasses for
atherosclerotic occlusive disease of the legs was conducted. Clinical data were recorded prospectively, and preoperative
levels of anti-PC IgM measured with the CVDeﬁne kit from Athera Biotechnologies (Solna, Sweden). The principal
clinical end point was the loss of primary patency (loss of graft ﬂow, or any intervention for stenosis). Patients were
followed regularly by duplex ultrasound at 1, 3, 6, 12, 18 months, and yearly thereafter.
Results: Fifty-six patients were studied, for an average of 1.3 years. Indications for surgery were claudication (33.9%),
ischemic rest pain (17.9%), and ischemia with ulceration or gangrene (48.2%). Seventeen (30.4%) patients experienced loss
of primary patency (10 graft occlusions, seven surgical or endovascular revisions of graft stenoses). Kaplan-Meier survival
analysis showed that the quartile of patients with the lowest anti-PC IgM levels had signiﬁcantly worse primary graft
patency (log-rank test, P [ .0085). Uni- and multivariate Cox proportional hazards analysis revealed that the preop-
erative anti-PC IgM level was an important predictor of graft failure. Patients with IgM values in the lowest quartile had
a 3.6-fold increased risk of graft failure (95% conﬁdence interval: 1.1-12.1), even after accounting for other signiﬁcant
clinical or technical factors such as indication for surgery, site of distal anastomosis, or vein graft diameter.
Conclusions: A naturally occurring IgM antibody directed against the proinﬂammatory epitope PC may be protective
against vein graft stenosis and failure, through anti-inﬂammatory mechanisms. Measurement of this antibody may be
a useful prognostic indicator, although larger studies of more diverse populations will be needed to conﬁrm these results.
The biological actions of anti-PC IgM suggest it may be useful in developing immunotherapies to improve bypass
longevity. (J Vasc Surg 2013;58:997-1005.)Atherosclerosis is an inﬂammatory, immune-mediated
disease.1-3 The appearance of oxidized lipids and related
pathologic neoantigens in the vessel wall are commonly
the inciting events that attract inﬂammatory cells to the
site of injury, beginning a cascade of inﬂammatory events
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://dx.doi.org/10.1016/j.jvs.2013.04.042proliferation, matrix deposition, and ultimately complex
plaque formation.3,4 Our increasing knowledge of arterial
injury and repair has led to an understanding that there
are common mechanisms of cellular and humorally medi-
ated inﬂammation that govern primary atherosclerosis,
neointimal hyperplasia, and adaptive vascular remodeling.
Although much research has emphasized the proinﬂamma-
tory mediators, some natural anti-inﬂammatory mecha-
nisms have also been known for some time.5
Among these are natural IgM antibodies that belong to
the innate immune system and are present at birth.6-8 These
natural antibodies are programmed to recognize a restricted
pattern of “danger signals” and, hence, protect against
bacterial invasion, control oxidative stress, and neutralize
proinﬂammatory oxidized lipid moieties.9,10 As outlined
by Lutz and others,8 during oxidative stress at sites of
vascular injury, the abundant lipid phosphatidylcholine
undergoes oxidation to expose normally hidden phosphor-
ylcholine (PC) head groups. Dying cells and cellular debris
also expose and release this neoantigen of PC, which is
recognized by the immune system as “altered self” and insti-
gates a complex inﬂammatory response.5 These normally
cryptic PC epitopes are also a prominent part of the capsular
polysaccharide of many bacteria. Thus, abnormally exposed
PC is one of the major antigens recognized by our innate
immune system.11 Research and diagnostic tools have now997
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exposed PC in humans and animals.12
The putative vascular protective mechanisms of this
antibody include the inhibition of macrophage uptake of
oxidized low-density lipoprotein, blockade of macrophage
interleukin-6 production,13 and suppression of endothelial
activation by inﬂammatory mediators.10,14 In vivo, anti-PC
IgM is thought to attenuate the inﬂammatory response to
PC that is exposed at sites of vascular injury. Low levels of
anti-PC IgM may, thus, lead to excessive activation of
inﬂammatory responses. In large human cohorts, low levels
of anti-PC IgM were associated with a signiﬁcantly
increased risk of stroke or myocardial infarction14-17 and
mortality in dialysis patients.18 Furthermore, in animal
models, enhancement of anti-PC antibodies through
immunization or supplementation reduced atherosclerosis
and intimal hyperplasia in a mouse vein bypass model.19,20
Twin studies suggest that 40% of the variability in human
anti-PC IgM levels is attributable to genetic variance.21
Autogenous vein grafts used to bypass atherosclerotic
occlusive disease of the lower extremities are prone to early
failure due to stenosis and thrombosis. Atherosclerosis, per
se, is not the cause of these early failures, which typically
occur within the ﬁrst 1 to 2 years after surgery.22 However,
both early graft failure and atherosclerosis have in common
the derangement of the injury/repair process by activation
of thromboinﬂammatory pathways, leading to intimal
hyperplasia, smooth muscle cell proliferation, and induc-
tion of a prothrombotic local vascular environment.
Thus, it is possible that anti-PC IgM antibodies might
modulate and normalize the vascular healing process in
vein grafts, just as they modulate the progression of cardio-
vascular arterial disease. Previous human studies illustrated
the importance of low levels of anti-PC IgM, as they were
associated with loss of atheroprotection and adverse events.
We conducted this pilot study to determine if there was
a relationship between low levels of anti-PC IgM anti-
bodies and the loss of primary patency of infrainguinal
autogenous vein grafts.
METHODS
We designed a prospective, longitudinal observational
study of all eligible patients undergoing infrainguinal
bypass at a single institution. After informed consent,
patients scheduled for elective, infrainguinal bypass surgery
using autologous vein were prospectively recruited at the
VA Puget Sound Health Care System, a large regional
referral center for vascular surgery. The research was
approved by the Institutional Review Board of the Human
Research Protection Program of the VA Puget Sound. All
elective infrainguinal bypasses using autogenous vein were
eligible for study. Exclusion criteria for the study were
operations for nonatherosclerotic or aneurysmal disease,
concurrent aortobifemoral or femoral-femoral bypass, use
of a prosthetic bypass conduit, active treatment for malig-
nancy (ie, chemotherapy), chronic hemodialysis, periopera-
tive thrombosis of the graft, or a diagnosed systemic
inﬂammatory disease (eg, lupus or other treatment withimmunosuppressive drugs) or thrombophilia. At surgery,
completion intraoperative imaging was performed in all
cases (angiography or duplex ultrasound) to conﬁrm
patency and freedom from stenosis or technical defects.
Patients were classiﬁed as diabetic if the diagnosis was in
their problem list, and they were being chronically treated
with an oral hypoglycemic agent or insulin. Active smoking
was self-reported by the patient. We included as “smokers”
those who had quit in the past week prior to surgery. The
nonsmoker classiﬁcation included those former smokers
who had quit months to years previously.
The clinical severity of their occlusive disease at the
time of surgery (leg status) was classiﬁed as claudication
(Fontaine stage II, Rutherford grade I), rest pain (Fontaine
stage III, Rutherford grade II), or critical ischemia with
ulceration (Fontaine stage IV, Rutherford grade III),
according to the guidelines of the Society for Vascular
Surgery.23 Several other surgical factors known to inﬂuence
the primary patency of lower extremity bypass grafts were
also recorded prospectively: a history of a previously failed
bypass graft, the location of the distal anastomosis, and the
minimum diameter of the pressurized vein conduit. Finally,
technical aspects of the surgical procedures that have been
associated with a higher risk of failure were noted, which
we denoted as higher-risk vein graft. This factor was
considered positive if veins other than the great saphenous
vein were used in part or whole or if there were any tech-
nical problems during surgery requiring intraoperative
revisions.
The long-term patency of the grafts was monitored by
arterial color duplex ultrasound and ankle-brachial indices
at 4 to 6 weeks, then at 3, 6, 12, 18 months, and yearly
thereafter. Standard duplex graft surveillance was per-
formed on Acuson Antares equipment (Siemens USA),
using protocols established by Bandyk et al.24,25 The
primary clinical end point was the loss of primary patency
(graft failure), deﬁned as any graft revision to maintain
patency, or graft thrombosis. The ﬁrst of these events to
occur triggered the primary end point. Graft revision was
deﬁned as any open surgical or endovascular procedure
performed on a patent graft to correct stenosis or narrow-
ing. The treating surgeon made the independent clinical
decision regarding the need for revision, based on the
accepted deﬁnitions for a hemodynamically signiﬁcant
vein graft stenosis (ie, diameter reduction of >75%, peak
systolic velocity >300 cm/s, velocity ratio >3.5).25 Graft
occlusion was deﬁned (per published guidelines23) as clin-
ical loss of ﬂow, which was conﬁrmed by complementary
imaging when necessary.
Peripheral blood samples were obtained to measure
anti-PC IgM preoperatively, using evacuated tubes con-
taining potassium-ethylenediaminetetraacetic acid (1.8
mg/mL ﬁnal concentration; Becton Dickinson, Franklin
Lakes, NJ). Within 1 hour of collection, the tubes were
centrifuged at 200 g for 10 minutes at room tempera-
ture, and the platelet-rich plasma was transferred to poly-
propylene microcentrifuge tubes. These tubes were
centrifuged at 13,000 g for 10 minutes, and the





Age, years 64.8 63.0 50-81
Follow-upeall patients, days 464 377 31-1580
















Ankle-brachial index 0.46 0.47 0-0.96
White blood cell count, K/uL 8.2 7.7 5-13.6
Prior failed graft 12.5
Operative factors
Above knee distal anastomosis 33.9
Below knee distal anastomosis 28.6
Tibial distal anastomosis 37.5
High-risk vein graft 23.2
Diameter of vein, mm 4.06 4.00 3-7
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at 70 until assay. The manufacturer of the kits states
that samples tolerate at least three to four cycles of freeze
thawing, although this was avoided by making aliquots.
IgM anti-PC is also stable for years at 70C. Anti-PC
IgM levels were determined by enzyme-linked immunosor-
bent assay using the CVDeﬁne kit (Athera Biotechnologies,
Solna, Sweden),12 an enzyme-linked immunosorbent assay
that employs an immobilized, conjugated PC antigen, and
human anti-PC IgM for standards. Brieﬂy, thawed plasma
was centrifuged 5 minutes at 13,000 g to remove aggre-
gates, then diluted as directed in the provided assay diluent.
Samples, standards, and controls provided in the kit were
added in duplicate to microwells coated with PC. After
washing, the bound IgM was reacted with anti-IgM conju-
gated to horseradish peroxidase, measured with 3,30,5,50-
tetramethylbenzidine as substrate. The standard curve was
generated using the cubic spline algorithm (GraphPad
Prism, San Diego, Calif), and sample concentrations were
expressed as arbitrary units/mL as deﬁned by the
manufacturer.
Statistical analyses. Analyses were conducted in the
statistical software package R (v. 2.15.2). Survival analyses
were made with the Kaplan-Meier survival curve and the
Cox proportional hazard model, stratiﬁed by dichotomiza-
tion of anti-PC IgM values into the lowest 25% and the
remaining 75%. This was justiﬁed by the biological
behavior of this IgM antibody, as observed in clinical
studies. The univariate and multivariate Cox regression
analyses are presented as hazard ratios (95% conﬁdence
intervals). Cox adjustments were done with correction for
the known predictors of graft failure outlined below.
Values of IgM were log-transformed where noted. Log
rank tests were also completed to determine whether the
survival distributions between groups were equal. To
determine if the value of preoperative IgM was associated
with clinical characteristics of the patients, uni- and
multivariate linear regression models were completed for
each clinical parameter.
RESULTS
Patient characteristics. A total of 68 patients were
initially recruited to the study. Eight of these patients
were excluded from further study because they did not
have a qualifying operation (eg, prosthetic graft, or never
had surgery), three had perioperative occlusions before
discharge, and one was excluded for lack of intraoperative
completion imaging. All of the subsequent primary end
points in the remaining 56 patients occurred more than
30 days after their surgery. Thus, 56 consecutive, eligible
patients were enrolled in the study between 2007 and
2012, and all had their levels of plasma anti-PC IgM
antibodies measured preoperatively. Fifty-four subjects
were Caucasian, two African American, and three were
female. Table I describes the main characteristics of these
subject’s medical conditions, their mean and median
follow-up, and the relevant details of their surgeries.
Thirteen patients received the designation of higher-riskvein graft based on technical aspects of the surgery (veins
other than the great saphenous, three patients) or any
technical problems requiring intraoperative revisions (10
patients). Technical revisions included autogenous patch
angioplasties of narrow anastomoses, and intraoperative
repairs or resections of venous conduit abnormalities.
Relationship between anti-PC IgM levels and
outcomes. The average preoperative IgM value was 74.4
units/mL (611.9 standard error of the mean) and the
median was 38.0 units/mL. The values were not normally
distributed, so a log transformation was completed, and the
log values were normally distributed. Seventeen of the 56
patients experienced a primary end point (30.4%), of which
10 were graft occlusion, and seven graft revisions for
a hemodynamically signiﬁcant stenosis. The clinical charac-
teristics of these patients are described in Supplementary
Table I, online only.
The primary patency of the overall group is presented
as a Kaplan-Meier survival curve in Fig 1. For survival anal-
ysis of the effect of anti-PC IgM, the preoperative values
were dichotomized, comparing those in the lowest quartile
(n ¼ 14) to the other 75% (n ¼ 42). This analytic approach
was taken because prior research suggests that low levels of
IgM are speciﬁcally associated with the loss of protective
effects, whereas a much wider range of higher levels are
associated with freedom from adverse outcomes. Those
patients in the lowest quartile experienced a signiﬁcantly
inferior primary graft survival, compared with the higher
75% (log-rank test, P ¼ .0085; Fig 2). We tested alternative
Fig 1. Kaplan-Meier survival analysis of overall primary graft patency. Freedom from loss of primary patency is illus-
trated for all 56 patients studied. The numbers above and below the graph lines indicate the number of subjects at risk
at each interval. Standard errors of the mean are shown.
Fig 2. Kaplan-Meier survival analysis of overall primary graft patency according to IgM level. The difference in primary
graft patency (stenosis requiring intervention, and graft occlusion) between those in the bottom quartile of anti-
phosphorylcholine (PC) IgM values, and those in the top 75% was signiﬁcant (log-rank test, P ¼ .0085). The
numbers above and below the graph lines indicate the number of subjects at risk at each interval. Standard errors of the
mean are shown, with truncation of the graph to 600 days, where the standard error of the mean of the primary group
exceeds 10%.
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quintile vs the highest 80%, or those below the median
value vs those above. Each of these analyses (log-rank
test, P ¼ .019 and .035, respectively) were statisticallysigniﬁcant, but stratiﬁcation by the lowest quartile gave
the best discrimination of clinical outcome. Graft survival
was also analyzed from the perspective of freedom from
intervention for stenosis, excluding those primary end
Fig 3. Kaplan-Meier survival analysis of freedom from stenosis according to IgM level. Considering the end point of
stenosis (requiring intervention) alone, the differences in graft survival were signiﬁcant (log-rank test, P ¼ .023).
Technical details of the graph are the same as Fig 2.
Fig 4. Anti-phosphorylcholine (PC) IgM levels according to
primary graft patency. Forty-two subjects with at least 1 full year of
follow-up were included. The box plots show the mean (dotted
line), median (solid line), 25-75 percentile (box), and 10-90
percentile (error bars). P ¼ .015, Mann-Whitney rank sum. The
central scatter plot illustrates the range of preoperative IgM values
among all 56 patients.
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the Kaplan-Meier curves and shows that those patients in
the lowest quartile of anti-PC IgM values had a higher inci-
dence of graft stenosis (log-rank test, P ¼ .023).
The preoperative IgM values were signiﬁcantly lower in
those subjects who suffered loss of primary patency
(median, 27.9 units/mL; interquartile range, 20.45-
55.08) compared with those whose grafts remained patent
(median, 46.1; interquartile range, 34.78-134.02).
Because the majority of graft failures occur within the ﬁrst
year of follow-up, we included only the 42 subjects with at
least 1 full year of surveillance of their patent grafts. Fig 4
illustrates these differences, which were signiﬁcant (P ¼
.015, Mann-Whitney rank sum test) and also illustrates
a scatter plot of all preoperative values.
To identify the speciﬁc factors that might be associated
with the duration of primary patency, we performed Cox
proportional hazards analyses of the entire cohort of
56 patients, ﬁrst testing individually the variables that
might affect the loss of primary patency (Table II). The
variables that were individually signiﬁcant at alpha level
.05 were distal anastomosis (P ¼ .02, tibial vs above
knee), minimum vein diameter (P ¼ .001), and preopera-
tive IgM. The variables of leg status (P ¼ .06, ulceration
vs claudication) and high-risk vein graft (P ¼ .07) were
of borderline signiﬁcance, so they were included in the
multivariate Cox proportional hazards model. Subsequent
multivariate analysis yielded a parsimonious model for
graft failure in which the minimum vein graft diameter
and the preoperative anti-PC IgM value were the two
most signiﬁcant factors associated with graft failure.Table III shows that patients in the lowest quartile of
anti-PC IgM values (below w27 units/mL) had a 3.62-
fold greater risk of graft failure than the other 75%,
even accounting for the diameter of vein conduit, leg
status, site of distal anastomosis, and high-risk vein graft
characteristics. Also, for each 1-mm reduction in vein graft
diameter from the median (4 mm), the risk of graft failure
increases by 5.56-fold, after adjustment for distal
Table II. Univariate Cox proportional hazards modeleloss of primary patency
Variable Level Hazard ratio Lower 95% Upper 95% P value for Z statistic
Age, years - 1.04 0.98 1.11 .22
Leg status (reference level ¼ claudication) Rest pain 1.81 0.40 8.13 .44
Ulceration 3.20 0.96 10.67 .06
Diabetes Yes 1.54 0.59 3.99 .38
Smoker Yes 1.03 0.39 2.71 .96
Distal anastomosis (reference level ¼ above knee) Below knee 1.94 0.43 8.73 .39
Tibial 5.05 1.29 19.77 .02
Prior failed graft Yes 2.22 0.70 7.00 .18
High-risk vein graft Yes 2.53 0.91 7.02 .07
Index leg ankle-brachial index (for each .10 decrease) - 1.19 0.96 1.48 .11
Minimum diameter - 0.23 0.10 0.56 .001
Preoperative IgM valueequintile Lowest 20% 3.37 1.15 9.87 .03
Preoperative IgM valueequartile Lowest 25% 3.53 1.30 9.58 .01
Preoperative IgM valueemedian Below median 2.94 1.03 8.40 .04
These clinical characteristics were tested individually for their relationship to the occurrence of the primary end point over time. The preoperative IgM value,
whether considered as the lowest quintile, quartile, or below the median, was signiﬁcantly associated with loss of primary patency. The following factors were
chosen for inclusion in the subsequent multivariate hazards model because they were signiﬁcant, or approached signiﬁcance: leg status, distal anastomosis,
high-risk vein graft, minimum diameter, and lowest quartile of IgM value.
Table III. Multivariate Cox proportional hazards modeleloss of primary patency
Variable Level Hazard ratio Lower 95% Upper 95% P value for Z statistic
Leg status (reference level ¼ claudication) Rest pain 1.07 0.21 5.40 .93
Ulceration 1.40 0.36 5.48 .63
Distal anastomosis (reference level ¼ above knee) Below knee 2.68 0.56 12.74 .22
Tibial 2.86 0.59 13.87 .19
High-risk vein graft Yes 1.51 0.45 5.09 .50
Minimum diameter (for each decrement of 1 mm
from median)
- 5.56 1.94 15.95 .001
Preoperative IgM valueequartile Lowest 25% 3.62 1.08 12.07 .037
In this multivariate hazards model, minimum diameter of the vein graft and the lowest quartile of preoperative IgM values were signiﬁcantly associated with
loss of primary patency.
Table IV. Univariate Cox proportional hazards modelegraft stenosis
Variable Level Hazard ratio Lower 95% Upper 95% P value for Z statistic
Age, years - 1.04 0.94 1.15 .49
Leg status (reference level ¼ claudication) Rest pain 0.82 0.085 7.96 .87
Ulceration 1.74 0.32 9.61 .53
Diabetes Yes 0.69 0.13 3.57 .66
Smoker Yes 1.63 0.31 8.44 .56
Distal anastomosis (reference level ¼ above knee) Below knee 1.01 0.17 6.06 .99
Tibial 1.33 0.2 8.98 .77
Prior failed Yes 3.87 0.65 23.23 .14
High-risk vein graft Yes 4.92 0.96 25.09 2.06
Minimum diameter (for each decrement of 1 mm
from median)
- 2.07 0.56 7.62 .27
Index leg ankle-brachial index (for each .10 decrease) - 1.07 0.74 1.54 .73
Preoperative IgM valueequartile Low 25% 5.47 1.07 27.87 .04
These clinical characteristics were tested individually for their relationship to the occurrence of the end point of graft stenosis. The following factors were
chosen for inclusion in the subsequent multivariate hazards model because they were signiﬁcant, or approached signiﬁcance: Prior failed graft, high-risk vein
graft, and lowest quartile of IgM value.
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erative IgM quartile.
We conducted a similar analysis, considering exclusive-
ly the end point of graft stenosis greater than 75% (all of
which underwent intervention and lost primary patency).Tables IV and V illustrate the univariate and multivariate
analyses. By univariate analysis, the preoperative IgM quar-
tile was signiﬁcant, and the characteristics of prior failed
bypass and high-risk vein graft were of borderline signiﬁ-
cance. Including all these in a multivariate analysis shows
Table V. Multivariate Cox proportional hazards modeldgraft stenosis
Variable Level Hazard ratio Lower 95% Upper 95% P value for Z statistic
Prior failed Yes 3.45 0.39 30.83 .27
High-risk vein graft Yes 3.5 0.47 26.03 .22
Preoperative IgM value e quartile Low 25% 7.79 1.27 47.82 .027
Log rank test, P ¼ .013 for this model.
In this multivariate hazards model, the lowest quartile of preoperative IgM values was signiﬁcantly associated with graft stenosis requiring intervention.
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a 7.8-fold increased risk of graft stenosis requiring revision.
Relationship between clinical factors and IgM
levels. Patients with different clinical characteristics (eg,
diabetes or indication for surgery) might disproportionately
have higher or lower IgM values. To investigate these rela-
tionships, we performed univariate and multivariate linear
regressions. Neither analysis revealed any signiﬁcant statis-
tical relationship between IgM values and the clinical char-
acteristics (age, leg status, diabetes, smoking, distal
anastomosis, prior failed graft, high-risk vein graft, and
minimum diameter). These results are summarized in the
Supplementary Table II, online only. The values of
preoperative anti-PC IgM were not signiﬁcantly different
between diabetics/nondiabetics, or according to indication
for surgery (Supplementary Table III, online only).
Twenty-eight percent of the lowest quartile of IgM values
had high-risk bypasses, and 21% of the highest three
quartiles had high-risk bypasses. This difference was not
signiﬁcant (Fisher exact test, P ¼ 1.0).
DISCUSSION
This most durable of infrainguinal revascularization
procedures, lower extremity bypass with vein, is still prone
to stenosis and graft failure that can affect 20% to 35% of
infrainguinal grafts within the ﬁrst year of surgery.22,26-28
In this prospective, longitudinal study, we have shown
that the preoperative level of a naturally occurring IgM
antibody directed against the inﬂammatory antigen, PC is
closely associated with the primary patency of autogenous
infrainguinal vein grafts. Even accounting for other well-
known factors that inﬂuence the longevity of bypass grafts,
such as the severity of occlusive disease, the quality of the
vein conduit, and technical aspects of the surgery, the
preoperative anti-PC IgM value was a signiﬁcant predictor
of loss of primary patency. When the analysis was restricted
to loss of primary patency because of hemodynamically
signiﬁcant vein graft stenosis, the results were similar.
We conﬁrmed that Fontaine class, the site of the distal
anastomosis, vein diameter, and intraoperative technical
factors, when considered individually, may be prognostic
indicators of future vein graft stenosis and occlusion.29-32
They are useful in postoperative decision making regarding
antithrombotic therapy and the intensity of graft surveil-
lance. Until now, biological measurements that directly
reﬂect a patient’s predisposition to graft stenosis or occlu-
sion have been lacking. Our data suggest that the preoper-
ative level of anti-PC IgM may be another potential toolfor prognostication and postoperative management. The
mechanisms of action of this natural IgM may also lend
new insights into the mechanisms of graft failure, and the
development of preventative strategies.
Previous studies of anti-PC IgM and cardiovascular
disease have shown that low levels are most predictive of
adverse outcomes. Many studies suggest that a wide range
of IgM levels might be healthy, whereas levels below
a certain threshold lead to the loss of anti-inﬂammatory,
atheroprotective effects, which is why we analyzed the
IgM values as a discrete variable. Fiskesund and
colleagues, in a study of 227 subjects with 455 matched
controls found the strongest association between IgM
and ﬁrst stroke below the 30th percentile of IgM values.
The association with stroke was more pronounced at
lower percentiles and primarily in women but not in
men.15 Population-based studies involving almost 5000
subjects, from the Malmo Diet and Cancer Study cohort
and a Stockholm screening project, found that low levels
of anti-PC IgM were most strongly associated with
cardiovascular events in men.14,33 The interactions
between sex and anti-PC IgM effects are still unclear.
Women in general have higher levels of this IgM, which
may be one factor contributing to the lower incidence
and later onset of vascular disease in females.33,34 Our
current study cannot resolve this issue, as our subjects
were predominantly male.
The vascular-protective mechanisms of anti-PC IgM
center on its ability to block cellular inﬂammatory
responses to PC. This epitope is normally hidden but
becomes exposed when low density lipoprotein becomes
oxidized, when there is cellular damage and death, or
when certain bacteria are present. Su et al found that the
expression of adhesion molecules by human endothelial
cells in response to platelet activating factor (itself a PC
derivative) was inhibited by anti-PC IgM.35 de Faire and
colleagues demonstrated that anti-PC IgM blocked the
uptake of oxidized low-density lipoprotein by macro-
phages.14 Research in animal models has shown that
inducing higher levels of anti-PC IgM retards the progres-
sion of atherosclerosis and prevents vein graft thickening,
providing evidence of a cause and effect relationship.20,36
These studies suggest that the innate anti-PC IgM anti-
body may play an important role in the modulation of
vascular inﬂammation.
As in atherosclerosis, vascular inﬂammation is a key
factor in graft failure. Although the etiologies of autogenous
graft failure are complex and diverse, loss of primary patency
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plasia and constrictive remodeling.37,38 The activation of
inﬂammatory and thrombotic pathways (which are tightly
intertwined) is thought to be a prime driver of the derange-
ments of vascular healing that result in graft stenosis and
failure.22,39 Patients with peripheral arterial occlusive disease
are known to have pathologic activation of these thromboin-
ﬂammatory pathways.40,41
Synthesizing our current knowledgedthat anti-PC
IgM plays an anti-inﬂammatory role against the appearance
of a common inﬂammatory molecule; that vascular inﬂam-
mation contributes to graft stenosis and failure; and that
patients with peripheral arterial occlusive disease have exag-
gerated inﬂammatory proﬁlesdthe results of our current
study are consistent and conﬁrmatory. Patients with the
lowest levels of anti-PC IgM were signiﬁcantly more prone
to graft failure than those with higher levels.
Biological strategies to abrogate the deranged response
to injury have uniformly failed in humans, and the human
variability in the response to vascular injury is poorly under-
stood. The biological actions of anti-PC IgM raise the
possibility of new strategies to normalize vascular healing,
by suppressing of one of the earliest events in vascular
healingdthe exposure of inﬂammatory PC. Such strategies
could include conferring passive immunity by the adminis-
tration of an engineered anti-PC antibody to those patients
with low levels, or the induction of enhanced immunity by
vaccination. Both strategies have been successful in animal
models.19,20
This study has limitations. This was an observational
study, so we did not dictate patient management or antith-
rombotic treatments. Some variables, like the use of aspirin
(92.9%) and statins (80.4%) were so highly prevalent that
analysis of their inﬂuence on primary patency was not
possible. The study population does not shed light on
possible sex or racial differences in anti-PC IgM levels,
nor the prognostic signiﬁcance of such factors. We are
currently conducting larger and broader studies to address
these questions. Despite these limitations, and in spite of
a relatively small cohort, the relationship between anti-PC
IgM levels and loss of primary patency was strong and
consistent, even after accounting for other important
variables.
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Supplementary Table I (online only). Clinical
characteristics of losses of primary patency
Occlusion (n ¼ 10) Stenosis (n ¼ 7)
Leg status
Claudication 1 3
Rest pain 2 1
Ulceration 7 3





AK, Above knee; BK, below knee.




categorical Level P value
Age Continuous - .48
Leg status at entry Categorical (3) Rest pain .97
Ulceration .09
Diabetes Categorical (2) Yes .36
Smoker Categorical (2) Yes .31
Distal anastomosis Categorical (3) Below knee .28
Tibial .42
Prior failed Categorical (2) Yes .71
High risk vein graft Categorical (2) Yes .45
Minimum diameter Continuous - .49
Index keg ABI Continuous - .63
ABI, Ankle-brachial index; PC, phosphorylcholine.
The relationships between the clinical characteristics of the patient pop-
ulation and the preoperative anti-PC IgM level were tested. IgM values
were log transformed. The univariate analysis revealed no statistical rela-
tionship between IgM values and the clinical characteristics listed. A
multivariate regression model including all of these clinical characteristics
did not reveal any signiﬁcant relationships either. Correlation coefﬁcients
analysis showed no relationship between vein graft diameter and IgM
quartile, nor did logistic regression reveal any unequal distribution of vein
graft diameters between the lowest quartile and highest 75% of IgM values
(not shown).
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Supplementary Table III (online only). Median values of preoperative anti-PC IgM by clinical characteristic
Characteristic Status Median IgM, U/mL 25% CI 75% CI P valuea
Diabetes No 37.3 24.5 64.5
Yes 41.4 27.7 110.6 .48
Leg status Claudication 43.2 33.4 105.4
Rest pain/ulcer 34.9 20.4 66.8 .18
CI, Conﬁdence interval; PC, phosphorylcholine.
The median values of preoperative IgM were not signiﬁcantly different according to diabetic status or preoperative leg status (ie, indication for surgery).
aMann-Whitney rank sum test.
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